{"id":60476,"date":"2024-10-12T00:05:38","date_gmt":"2024-10-12T00:05:38","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/12\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/"},"modified":"2024-10-12T00:05:38","modified_gmt":"2024-10-12T00:05:38","slug":"mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/","title":{"rendered":"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN"},"content":{"rendered":"<div>\n<p align=\"justify\">DALLAS, TX, Oct.  11, 2024  (GLOBE NEWSWIRE) &#8212; Mangoceuticals, Inc. (NASDAQ: MGRX) (\u201c<u>MangoRx<\/u>\u201d or the \u201c<u>Company<\/u>\u201d), a company focused on developing, marketing, and selling a variety of men\u2019s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-15 (the \u201c<u>Reverse Stock Split<\/u>\u201d). The Reverse Stock Split will become effective on October 16, 2024 at 12:01 a.m. Eastern Time (the \u201c<u>Effective Time<\/u>\u201d), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on October 16, 2024. In connection with the Reverse Stock Split, every fifteen shares of the Company\u2019s common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company\u2019s common stock. No change will be made to the trading symbol for the Company\u2019s shares of common stock, \u201cMGRX\u201d, in connection with the reverse split.<\/p>\n<p align=\"justify\">The Reverse Stock Split is part of the Company\u2019s plan to regain compliance with the minimum bid price requirement of\u00a0$1.00\u00a0per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.<\/p>\n<p align=\"justify\">The Reverse Stock Split was approved by the Company\u2019s stockholders at the Company&#8217;s Special Meeting of Stockholders held on\u00a0March 25, 2024\u00a0(the \u201c<u>Special Meeting<\/u>\u201d) to be effected in the Board\u2019s discretion within approved parameters. Following the Special Meeting, the final ratio was approved by the Company\u2019s Board.<\/p>\n<p align=\"justify\">The Reverse Stock Split will reduce the number of shares of the Company&#8217;s outstanding common stock from approximately 35.5 million shares (as of the date of this press release) to approximately 2.4 million shares, subject to adjustment for rounding, as discussed below and potential additional issuances through the effective date of the Reverse Stock Split.<\/p>\n<p align=\"justify\">The reverse split will affect all issued and outstanding shares of common stock. All outstanding options and other securities entitling their holders to purchase or otherwise receive shares of common stock will be adjusted as a result of the reverse split, as required by the terms of each security, and in certain cases, subject to reset rights. The number of shares available to be awarded under the Company\u2019s equity incentive plan will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 par value per share. The reverse split will not change the authorized number of shares of common stock or preferred stock. No fractional shares will be issued in connection with the reverse split, and stockholders who would otherwise be entitled to receive a fractional share will instead receive one whole share of common stock in lieu of such fractional share.<\/p>\n<p align=\"justify\">Additional information regarding the reverse stock split is available in the Company\u2019s definitive proxy statement originally filed with the U.S. Securities and Exchange Commission (SEC) on March 1, 2024 and a Current Report on Form 8-K which the Company filed today with the SEC.<\/p>\n<p align=\"justify\"><strong>About MangoRx<\/strong><\/p>\n<p align=\"justify\">MangoRx is focused on developing a variety of men&#8217;s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men&#8217;s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx\u2019s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx\u2019s partner compounding pharmacy and right to the patient\u2019s doorstep. To learn more about MangoRx\u2019s mission and other products, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u6GccGcFSsuHWEP60WmpzqTEBvVOvIJvmfdjm5EetpCbV_8WKg_MgfQqCbU7VEYrN_0rRdwxs54ZuEwURRjf_g==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>www.MangoRx.com<\/u><\/a> or on social media @Mango.Rx.<\/p>\n<p align=\"justify\"><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"justify\">Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (\u201cforward-looking statements\u201d). These forward-looking statements represent the Company\u2019s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as \u201cestimate,\u201d \u201cexpects,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cforesee,\u201d \u201cforecast,\u201d \u201clikely,\u201d \u201cwill,\u201d \u201ctarget\u201d or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company\u2019s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, our ability to maintain the listing of our common stock on Nasdaq; our ability to meet Nasdaq\u2019s minimum bid price requirement and other continued listing requirements of Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (\u201cFDA\u201d) and have not had the benefit of the FDA\u2019s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (\u201cFFDCA Act\u201d) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and\/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and\/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises\/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and\/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and\/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine\/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company\u2019s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.<\/p>\n<p align=\"justify\">More information on potential factors that could affect the Company\u2019s financial results is included from time to time in the \u201cCautionary Note Regarding Forward-Looking Statements,\u201d \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of the Company\u2019s filings with the SEC, including the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and subsequent reports. These filings are available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M0xfoTYlTYMKIS7ZOb2qQ-1aWcOlrS4moIsTGdVnUch3KPPk6cFCQuCsGzMBcUormQG0HcW8sNNSLy01H4Vi7A==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>www.sec.gov<\/u><\/a> and at our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gjfJFgBNshhfcPpvwXjzYm2SgsM4uCXCbCPQZRsSMj7BPCLAWb--8na786UT8_ihS0oMO3Ur1-i87J3k59ej5KwPSlKnHDGP8iOW9KAuD4xsiUFC8DRsahqB4Jy8TVLnQEfy4n4VCzxYaUB6o2iIKg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>https:\/\/www.mangoceuticals.com\/sec-filings<\/u><\/a>. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company\u2019s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.<\/p>\n<p align=\"justify\">Follow MangoRx on social media:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gjfJFgBNshhfcPpvwXjzYmhr3-ZeZP6kLQGtLXcHLhD4B7DScGB2AVga8UswEniV1tlbt51WfgYd_0A_rmgF1iC3l-DG9UF0bZO6E59Y17KIqlsyp9UgXi9Nk3RwZlyG\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>https:\/\/www.instagram.com\/mango.rx<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gjfJFgBNshhfcPpvwXjzYpfRHW2PxbFfuZjkM9IKLE4GAIGORT8gke5U2wVUiLHOMht55QQFZvD6bzTx5Ajesqsqt9WOQzz7vasgOj1GYQQ=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>https:\/\/x.com\/mango_rx<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gjfJFgBNshhfcPpvwXjzYuMEOuwSqtRnOijSKxFV2Y3gwWnnSIU_soJFNsiPi7c1Dc8FiiKTfmW-kMPfpqGXFnw5lcxvHBKync_Lhykyassb5GEz0bvJHkOaoDcZ0_ruRFItkzdARYJ6pyGpCtY5sg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>https:\/\/www.facebook.com\/MangoRxOfficial<\/u><\/a><\/p>\n<p align=\"justify\">FOR INVESTOR RELATIONS<\/p>\n<p align=\"justify\">Mangoceuticals Investor Relations<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FLH78kdg8pgdqmd1FOhFjLOywVz1pBjsqeT8Fuy58SjodMCyKJYGnakJnA6iHeuxHSVcT6sHHqWXEVdju9vIe89PfYyUVj4r8d1dsoEpoAw=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>investors@mangorx.com<\/u><\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2I0MjUyMzMtMDQwOS00YWMzLTg4ZGUtZmQwODgyYTViZTJkLTUwMDExNjEwNQ==\/tiny\/Mangoceuticals-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) &#8212; Mangoceuticals, Inc. (NASDAQ: MGRX) (\u201cMangoRx\u201d or the \u201cCompany\u201d), a company focused on developing, marketing, and selling a variety of men\u2019s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced that it will conduct a reverse [&#8230;]\n","protected":false},"author":1,"featured_media":60477,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60476","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN\" \/>\n<meta property=\"og:description\" content=\"DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) &#8212; Mangoceuticals, Inc. (NASDAQ: MGRX) (\u201cMangoRx\u201d or the \u201cCompany\u201d), a company focused on deve\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-12T00:05:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Mangoceuticals-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN\",\"datePublished\":\"2024-10-12T00:05:38+00:00\",\"dateModified\":\"2024-10-12T00:05:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/\"},\"wordCount\":1718,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/\",\"name\":\"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-12T00:05:38+00:00\",\"dateModified\":\"2024-10-12T00:05:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/","og_locale":"en_US","og_type":"article","og_title":"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN","og_description":"DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) &#8212; Mangoceuticals, Inc. (NASDAQ: MGRX) (\u201cMangoRx\u201d or the \u201cCompany\u201d), a company focused on deve","og_url":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-12T00:05:38+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Mangoceuticals-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN","datePublished":"2024-10-12T00:05:38+00:00","dateModified":"2024-10-12T00:05:38+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/"},"wordCount":1718,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/","url":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/","name":"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-12T00:05:38+00:00","dateModified":"2024-10-12T00:05:38+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT\u00a0AS PART OF NASDAQ COMPLIANCE PLAN"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60476"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60476\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60477"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}